This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Alloimmune blood transfusion reaction

Authoring team

Allo-immunisation may result from transfusion with red cells that are of different phenotype to the patient. Also, with repeated transfusions, the recipient may develop antibodies to leucocytes and platelets in the transfused blood.

Allo-immunisation usually occurs from days to weeks after infusion:

  • 75% of Rh negative patients given Rh positive blood develop antibodies to Rh D
  • more than 10% of repeatedly transfused patients develop antibodies to white cells and/or platelets

Prevention:

  • avoid transfusion of Rh D positive blood to Rh D negative patients
  • use filtered blood from which the majority of leucocytes and platelets have been removed

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.